EconPapers    
Economics at your fingertips  
 

Informed Conditioning on Clinical Covariates Increases Power in Case-Control Association Studies

Noah Zaitlen, Sara Lindström, Bogdan Pasaniuc, Marilyn Cornelis, Giulio Genovese, Samuela Pollack, Anne Barton, Heike Bickeböller, Donald W Bowden, Steve Eyre, Barry I Freedman, David J Friedman, John K Field, Leif Groop, Aage Haugen, Joachim Heinrich, Brian E Henderson, Pamela J Hicks, Lynne J Hocking, Laurence N Kolonel, Maria Teresa Landi, Carl D Langefeld, Loic Le Marchand, Michael Meister, Ann W Morgan, Olaide Y Raji, Angela Risch, Albert Rosenberger, David Scherf, Sophia Steer, Martin Walshaw, Kevin M Waters, Anthony G Wilson, Paul Wordsworth, Shanbeh Zienolddiny, Eric Tchetgen Tchetgen, Christopher Haiman, David J Hunter, Robert M Plenge, Jane Worthington, David C Christiani, Debra A Schaumberg, Daniel I Chasman, David Altshuler, Benjamin Voight, Peter Kraft, Nick Patterson and Alkes L Price

PLOS Genetics, 2012, vol. 8, issue 11, 1-13

Abstract: Genetic case-control association studies often include data on clinical covariates, such as body mass index (BMI), smoking status, or age, that may modify the underlying genetic risk of case or control samples. For example, in type 2 diabetes, odds ratios for established variants estimated from low–BMI cases are larger than those estimated from high–BMI cases. An unanswered question is how to use this information to maximize statistical power in case-control studies that ascertain individuals on the basis of phenotype (case-control ascertainment) or phenotype and clinical covariates (case-control-covariate ascertainment). While current approaches improve power in studies with random ascertainment, they often lose power under case-control ascertainment and fail to capture available power increases under case-control-covariate ascertainment. We show that an informed conditioning approach, based on the liability threshold model with parameters informed by external epidemiological information, fully accounts for disease prevalence and non-random ascertainment of phenotype as well as covariates and provides a substantial increase in power while maintaining a properly controlled false-positive rate. Our method outperforms standard case-control association tests with or without covariates, tests of gene x covariate interaction, and previously proposed tests for dealing with covariates in ascertained data, with especially large improvements in the case of case-control-covariate ascertainment. We investigate empirical case-control studies of type 2 diabetes, prostate cancer, lung cancer, breast cancer, rheumatoid arthritis, age-related macular degeneration, and end-stage kidney disease over a total of 89,726 samples. In these datasets, informed conditioning outperforms logistic regression for 115 of the 157 known associated variants investigated (P-value = 1×10−9). The improvement varied across diseases with a 16% median increase in χ2 test statistics and a commensurate increase in power. This suggests that applying our method to existing and future association studies of these diseases may identify novel disease loci. Author Summary: This work describes a new methodology for analyzing genome-wide case-control association studies of diseases with strong correlations to clinical covariates, such as age in prostate cancer and body mass index in type 2 diabetes. Currently, researchers either ignore these clinical covariates or apply approaches that ignore the disease's prevalence and the study's ascertainment strategy. We take an alternative approach, leveraging external prevalence information from the epidemiological literature and constructing a statistic based on the classic liability threshold model of disease. Our approach not only improves the power of studies that ascertain individuals randomly or based on the disease phenotype, but also improves the power of studies that ascertain individuals based on both the disease phenotype and clinical covariates. We apply our statistic to seven datasets over six different diseases and a variety of clinical covariates. We found that there was a substantial improvement in test statistics relative to current approaches at known associated variants. This suggests that novel loci may be identified by applying our method to existing and future association studies of these diseases.

Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1003032 (text/html)
https://journals.plos.org/plosgenetics/article/fil ... 03032&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pgen00:1003032

DOI: 10.1371/journal.pgen.1003032

Access Statistics for this article

More articles in PLOS Genetics from Public Library of Science
Bibliographic data for series maintained by plosgenetics ().

 
Page updated 2025-03-19
Handle: RePEc:plo:pgen00:1003032